China News Service, Harbin, April 22 (Reporter Jiang Hui) "Biomedicine is an important part of the biological industry. By 2025, the operating income of the biomedical industry in our province will strive to reach hundreds of billions..." On the 22nd, Heilongjiang Industrial Luo Feng, director of the Consumer Goods Industry Division of the Department of Information Technology, said in an interview with a reporter from Chinanews.com.

  Heilongjiang Province's bio-economy development plan, combined with the actual situation of the province, innovatively proposes to build six modern bio-industry systems with Longjiang characteristics: bio-medicine, bio-agriculture, bio-manufacturing, bio-energy, bio-environmental protection, and bio-medical engineering.

In 2021, 122 pharmaceutical manufacturing enterprises above designated size in Heilongjiang Province will achieve an operating income of 20.18 billion yuan, a year-on-year increase of 7.4%, accounting for 2.7% of the province's designated industry.

  "By 2025, the operating income of the biopharmaceutical industry in our province will strive to reach 100 billion level, the quality and efficiency will continue to improve, the transformation and upgrading will continue to accelerate, and it will enter a new stage of high-quality development of the entire industry chain." Luo Feng said that Heilongjiang pharmaceutical companies have drug approvals It has 8080 document numbers and has a number of well-known trademarks in China.

There are 9 listed companies and 3 top 100 companies in China's pharmaceutical industry.

Zeng Yuanyan has created a series of medium and large varieties of Shuanghuanglian, Acanthopanax senticosus, Manshanhong and Beidougen.

"Cold black soil" Chinese medicinal materials have a good growth environment and high quality. The supply of Acanthopanax senticosus, Banlangen and other medicinal materials account for 80% and 50% of the national market share respectively.

"Recently, our department has gathered the strength of the whole department to set up a special class for industrial revitalization, and a special class for the pharmaceutical industry under the special class for revitalization. There are 4 working groups for synthesis, planning, operation and empowerment, and organize the preparation of industrial action plans and annual plans. Etc., further refine the development ideas, clarify the division of tasks, strengthen work promotion, and promote the high-quality development of the pharmaceutical industry.”

  Zhang Jianhua, deputy director of the Consumer Goods Industry Division of the Department of Industry and Information Technology of Heilongjiang Province, said that in order to promote the leapfrog development of the bio-economy, Heilongjiang Province issued the "Several Policies and Measures to Support the High-quality Development of the Bio-economy in Heilongjiang Province".

For biopharmaceutical products that complete Phase I, Phase II, and Phase III clinical trials, a maximum reward of 10 million yuan will be given according to the category; a maximum reward of 10 million yuan will be given to enterprises that have obtained the registration certificate of biomedical products and are producing in Heilongjiang Province for the first time; For the first time the province has entered the top 100 enterprises in the national pharmaceutical industry or enterprises whose annual main business income exceeds 100 million yuan and entered the top 5 in the sub-industry will be rewarded with a maximum of 2 million yuan; New production projects such as production of Chinese herbal pieces and formula granules, extraction of Chinese herbal medicines, industrialization of classic recipes, and food health care will be given a maximum of 5 million yuan of financial support according to the scale of investment in fixed assets.

(Finish)